Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L01XE25
|
| gptkbp:brand |
gptkb:Mekinist
|
| gptkbp:CASNumber |
871700-17-3
|
| gptkbp:category |
antineoplastic agent
|
| gptkbp:chemicalFormula |
C26H23FIN5O4
|
| gptkbp:combinationTherapy |
gptkb:dabrafenib
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
4.5 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
trametinib
|
| gptkbp:indication |
BRAF V600E or V600K mutation-positive cancers
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:metabolism |
non-CYP mediated
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue hypertension rash cardiac dysfunction |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:anaplastic_thyroid_cancer melanoma |
| gptkbp:bfsParent |
gptkb:Mekinist
|
| gptkbp:bfsLayer |
5
|